Trial Profile
Phase II study of antineoplastons A10 and AS2-1 in patients with carcinoma of the adrenal gland
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Antineoplaston-A10 (Primary) ; Antineoplaston-AS2-1 (Primary)
- Indications Adrenal cancer
- Focus Therapeutic Use
- 27 Sep 2017 Status changed from recruiting to discontinued.
- 18 Aug 2005 New trial record.